- Home
- GAM vs NVAX Comparison
GAM vs NVAX Comparison
Compare GAM & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAM
- NVAX
- Stock Information
- Founded
- GAM 1927
- NVAX 1987
- Country
- GAM United States
- NVAX United States
- Employees
- GAM N/A
- NVAX N/A
- Industry
- GAM Investment Managers
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GAM Finance
- NVAX Health Care
- Exchange
- GAM Nasdaq
- NVAX Nasdaq
- Market Cap
- GAM 1.4B
- NVAX 1.3B
- IPO Year
- GAM N/A
- NVAX 1995
- Fundamental
- Price
- GAM $61.47
- NVAX $8.39
- Analyst Decision
- GAM
- NVAX Buy
- Analyst Count
- GAM 0
- NVAX 7
- Target Price
- GAM N/A
- NVAX $14.29
- AVG Volume (30 Days)
- GAM 20.1K
- NVAX 6.8M
- Earning Date
- GAM 01-01-0001
- NVAX 11-11-2025
- Dividend Yield
- GAM 5.74%
- NVAX N/A
- EPS Growth
- GAM N/A
- NVAX N/A
- EPS
- GAM 11.67
- NVAX 2.54
- Revenue
- GAM N/A
- NVAX $1,078,718,000.00
- Revenue This Year
- GAM N/A
- NVAX $61.69
- Revenue Next Year
- GAM N/A
- NVAX N/A
- P/E Ratio
- GAM $3.95
- NVAX $3.30
- Revenue Growth
- GAM N/A
- NVAX 9.22
- 52 Week Low
- GAM $37.32
- NVAX $5.01
- 52 Week High
- GAM $46.48
- NVAX $15.22
- Technical
- Relative Strength Index (RSI)
- GAM 78.57
- NVAX 56.61
- Support Level
- GAM $61.10
- NVAX $7.83
- Resistance Level
- GAM $61.79
- NVAX $8.31
- Average True Range (ATR)
- GAM 0.68
- NVAX 0.38
- MACD
- GAM 0.03
- NVAX 0.05
- Stochastic Oscillator
- GAM 74.50
- NVAX 74.84
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.